Patients’ characteristics at the onset of the PUK
| Case number | Sex, age (years) | Ocular dryness | History of extra-articular manifestations | Duration of RA (years) | Erosions | Anti-CCP | RF | ANA | Previous lines of bDMARD (n) | IS treatment at onset of PUK | CS (mg/day) | DAS-28 CRP |
| 1 | M, 61 | Yes | None | 12.7 | Yes | 288 | 240 | 1/160 | 4 | TCZ | 5 | 1.6 |
| 2 | M, 46 | Yes | None | 9.7 | Yes | 268 | 183 | No | 5 | TCZ | 0 | 5.2 |
| 3 | M, 55 | Yes | None | 9.6 | Yes | No | 31 | 1/160 | 3 | TCZ | NA | NA |
| 4 | F, 64 | No | None | 30.2 | Yes | 664 | 188 | No | 0 | MTX | 0 | 2.6 |
| 5 | F, 55 | Yes | Nodular scleritis 7 years before, scleritis concomitant with PUK | 21.3 | Yes | 164 | 47 | 1/160 | 2 | ETCPT+MTX | 0 | 2.2 |
| 6 | F, 60 | No | None | 14.1 | Yes | Yes | Yes | 1/320 | 1 | ETCPT+MTX | 0 | 2.1 |
| 7 | F, 65 | Yes | Purpura | 0 | No | >1000 | 348 | 1/320 | 0 | 0 | 0 | 4.5 |
ANA, antinuclear antibody; b-DMARD, biological disease-modifying antirheumatic drug; CCP, anticitrullinated peptide; CRP, C reactive protein; CS, corticosteroid; DAS-28, Disease Activity Score using 28 joint counts; ETCPT, etanercept; F, female; IS, immunosuppressive; M, male; MTX, methotrexate; NA, not applicable; PUK, peripheral ulcerative keratitis; RA, rheumatoid arthritis; RF, rheumatoid factor; TCZ, tocilizumab.